BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 21276604)

  • 1. Improved survival in non-Ashkenazi Jewish ovarian cancer patients with BRCA1 and BRCA2 gene mutations.
    Lacour RA; Westin SN; Meyer LA; Wingo SN; Schorge JO; Brooks R; Mutch D; Molina A; Sutphen R; Barnes M; Elder J; Teoh D; Powell CB; Choubey V; Blank S; Macdonald HR; Brady MF; Urbauer DL; Bodurka D; Gershenson DM; Lu KH
    Gynecol Oncol; 2011 May; 121(2):358-63. PubMed ID: 21276604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcome of neoadjuvant chemotherapy in BRCA1/2 mutation positive women with advanced-stage Müllerian cancer.
    Mahdi H; Gockley A; Esselen K; Marquard J; Nutter B; Yang B; Hinchcliff E; Horowitz N; Rose PG
    Gynecol Oncol; 2015 Dec; 139(3):407-12. PubMed ID: 26210778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer.
    Boyd J; Sonoda Y; Federici MG; Bogomolniy F; Rhei E; Maresco DL; Saigo PE; Almadrones LA; Barakat RR; Brown CL; Chi DS; Curtin JP; Poynor EA; Hoskins WJ
    JAMA; 2000 May; 283(17):2260-5. PubMed ID: 10807385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Founder BRCA 1 and 2 mutations among a consecutive series of Ashkenazi Jewish ovarian cancer patients.
    Tobias DH; Eng C; McCurdy LD; Kalir T; Mandelli J; Dottino PR; Cohen CJ
    Gynecol Oncol; 2000 Aug; 78(2):148-51. PubMed ID: 10926794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations.
    Levine DA; Argenta PA; Yee CJ; Marshall DS; Olvera N; Bogomolniy F; Rahaman JA; Robson ME; Offit K; Barakat RR; Soslow RA; Boyd J
    J Clin Oncol; 2003 Nov; 21(22):4222-7. PubMed ID: 14615451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.
    Alsop K; Fereday S; Meldrum C; deFazio A; Emmanuel C; George J; Dobrovic A; Birrer MJ; Webb PM; Stewart C; Friedlander M; Fox S; Bowtell D; Mitchell G
    J Clin Oncol; 2012 Jul; 30(21):2654-63. PubMed ID: 22711857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved survival in women with BRCA-associated ovarian carcinoma.
    Cass I; Baldwin RL; Varkey T; Moslehi R; Narod SA; Karlan BY
    Cancer; 2003 May; 97(9):2187-95. PubMed ID: 12712470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcomes of BRCA1/2 pathogenic variants in ovarian cancer cluster region in patients with primary peritoneal, epithelial ovarian, and fallopian tube cancer.
    Ha HI; Park EY; Eoh KJ; Lee YJ; Seo SS; Kang S; Park SY; Lim MC
    Gynecol Oncol; 2022 Feb; 164(2):415-420. PubMed ID: 34924242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Young Israeli women with epithelial ovarian cancer: prevalence of BRCA mutations and clinical correlates.
    Helpman L; Zidan O; Friedman E; Kalfon S; Perri T; Ben-Baruch G; Korach J
    J Gynecol Oncol; 2017 Sep; 28(5):e61. PubMed ID: 28657222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of BRCA1 and BRCA2 non-founder mutations in patients of Ashkenazi Jewish ancestry.
    Rosenthal E; Moyes K; Arnell C; Evans B; Wenstrup RJ
    Breast Cancer Res Treat; 2015 Jan; 149(1):223-7. PubMed ID: 25476495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study.
    Harter P; Johnson T; Berton-Rigaud D; Park SY; Friedlander M; Del Campo JM; Shimada M; Forget F; Mirza MR; Colombo N; Zamagni C; Chan JK; Imhof M; Herzog TJ; O'Donnell D; Heitz F; King K; Stinnett S; Barrett C; Jobanputra M; Xu CF; du Bois A
    Gynecol Oncol; 2016 Mar; 140(3):443-9. PubMed ID: 26740259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations.
    Robson M; Levin D; Federici M; Satagopan J; Bogolminy F; Heerdt A; Borgen P; McCormick B; Hudis C; Norton L; Boyd J; Offit K
    J Natl Cancer Inst; 1999 Dec; 91(24):2112-7. PubMed ID: 10601383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.
    Tan DS; Rothermundt C; Thomas K; Bancroft E; Eeles R; Shanley S; Ardern-Jones A; Norman A; Kaye SB; Gore ME
    J Clin Oncol; 2008 Dec; 26(34):5530-6. PubMed ID: 18955455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer.
    Kim SI; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS
    J Ovarian Res; 2019 May; 12(1):40. PubMed ID: 31064392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of nonfounder BRCA1/2 mutations in Ashkenazi Jewish patients presenting for genetic testing at a hereditary breast and ovarian cancer center.
    Frey MK; Kopparam RV; Ni Zhou Z; Fields JC; Buskwofie A; Carlson AD; Caputo T; Holcomb K; Chapman-Davis E
    Cancer; 2019 Mar; 125(5):690-697. PubMed ID: 30480775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ovarian cancer survival in Ashkenazi Jewish patients with BRCA1 and BRCA2 mutations.
    Ramus SJ; Fishman A; Pharoah PD; Yarkoni S; Altaras M; Ponder BA
    Eur J Surg Oncol; 2001 Apr; 27(3):278-81. PubMed ID: 11373105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer.
    Hyman DM; Zhou Q; Iasonos A; Grisham RN; Arnold AG; Phillips MF; Bhatia J; Levine DA; Aghajanian C; Offit K; Barakat RR; Spriggs DR; Kauff ND
    Cancer; 2012 Aug; 118(15):3703-9. PubMed ID: 22139894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Germline and Somatic BRCA1/2 Gene Mutational Status and Clinical Outcomes in Epithelial Peritoneal, Ovarian, and Fallopian Tube Cancer: Over a Decade of Experience in a Single Institution in Korea.
    Kim SI; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS
    Cancer Res Treat; 2020 Oct; 52(4):1229-1241. PubMed ID: 32718143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of BRCA germline mutations on breast cancer prognosis: A systematic review and meta-analysis.
    Baretta Z; Mocellin S; Goldin E; Olopade OI; Huo D
    Medicine (Baltimore); 2016 Oct; 95(40):e4975. PubMed ID: 27749552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRCA mutations and outcome in epithelial ovarian cancer (EOC): experience in ethnically diverse groups.
    Safra T; Lai WC; Borgato L; Nicoletto MO; Berman T; Reich E; Alvear M; Haviv I; Muggia FM
    Ann Oncol; 2013 Nov; 24 Suppl 8():viii63-viii68. PubMed ID: 24131973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.